Financials
- Market Capitalization 273.31 M
- Employee 35
- Founded 2008
- CEO N/A
- Website www.inhibikase.com
- Headquarter Delaware, United States
- FIGI BBG005TP2339
- Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-3.82
ratio cours/chiffre d'affaires
43.33
Related tickers
| # | Nom | Prix | 24h % | 7 jours % | 1M % | 1 an % | Cap Boursière | 7 Derniers Jours | |
|---|---|---|---|---|---|---|---|---|---|
| 3398 | NAGE Niagen Bioscience, Inc. - Common Stock | 3.47 USD | +5.47% | +2.97% | -1.42% | -30.32% | 276.37 M USD | ||
| 3405 | SABS SAB Biotherapeutics, Inc. - Common Stock | 3.62 USD | +0.56% | -3.98% | -7.18% | +29.29% | 276.80 M USD | ||
| 3420 | ALXO ALX Oncology Holdings Inc. - Common Stock | 2.04 USD | +2.00% | -12.45% | +28.30% | +334.04% | 274.51 M USD | ||
| 3422 | MGNX MacroGenics, Inc. - Common Stock | 4.33 USD | +0.93% | -7.08% | +4.34% | +188.67% | 275.23 M USD |